Biomind Labs Inc.
OTC: BMNDF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alejandro Antalich
- Employees
- 5
- Headquarters
- Canelones, Uruguay
- IPO year
- 2021
- Market cap
- $9.3M
- Website
- https://www.biomindlabs.com
Loading BMNDF…
Loading profile data…Frequently asked questions about BMNDF
What does Biomind Labs Inc. (BMNDF) do?
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Anot...
Where does BMNDF trade?
Biomind Labs Inc. (BMNDF) trades on the Other OTC.
What sector is BMNDF in?
Biomind Labs Inc. (BMNDF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Biomind Labs Inc.?
Alejandro Antalich is the chief executive officer of Biomind Labs Inc. (BMNDF).
Where is Biomind Labs Inc. headquartered?
Biomind Labs Inc. is headquartered in Uruguay.
Does BMNDF pay a dividend?
Biomind Labs Inc. (BMNDF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BMNDF go public?
Biomind Labs Inc. (BMNDF) completed its initial public offering in 2021.